ArticleBlood science (Baltimore, Md.)2022
NEK2, a promising target in TP53 mutant cancer.
Martina Cusan et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
2 papers cite it
this papercites it
ArticleBlood science (Baltimore, Md.)2022
Martina Cusan et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.